IP Library Granted Patent US 8,859,012
Granted Patent B2
US 8,859,012 · App. 12/714,598 · Granted Oct 14, 2014

Composition comprising

Inventors: Pui-Kwong Chan (Sugarland, TX); May Sung Mak (Hong Kong, CN); Yun Wang (Dunedin, NZ)
Assignee: Pacific Arrow Limited
A23L1/3002A23L1/3004A61K36/77C07H15/256A23V2002/00A61K36/00C07J63/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,859,012
App. No.
12/714,598
Granted
Oct 14, 2014
Kind
B2
Abstract

This invention provides compositions, methods and process of producing extracts and pure compounds from Xanthoceras sorbifolia . The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder. This invention provides compounds of oleanene triterpenoidal saponin in nature with the characteristics that at least one angeloyl group attache to Carbon 21 or/and 22, or/and linked to the sugar. The compounds of the present invention have various pharmaceutical and therapeutic applications.

Claims (28)

1. A method for treating or inhibiting cancer cell growth in a subject, comprising administering to the subject an effective amount of an extract obtained from Wenguanguo or Xanthoceras Sorbifolia , wherein the extract is obtained from the leaves, branches, stems, roots or barks of Wenguanguo or Xanthoceras Sorbifolia , wherein the cancer is breast cancer, leukocyte cancer, liver cancer, ovary cancer, bladder cancer, prostate cancer, bone cancer or brain cancer.

2. The method of claim 1 , wherein the extract comprises the following compound:

or chemical name: 3-O-[β-glucopyranosyl (1→2)]-α-arabinofuranosyl (1→3)-β-glucuronopyranosyl-21,22-O-diangeloyl-3β,16α,21β,22α,24β,28-hexahydroxyolean-12-ene, or Xanifolia-Y8.

3. The method of claim 1 , wherein the extract is obtained from the leaves of Wenguanguo or Xanthoceras Sorbifolia.

4. The method of claim 1 , wherein the extract is obtained from the roots of Wenguanguo or Xanthoceras Sorbifolia.

5. The method of claim 1 , wherein the extract is obtained from the barks of Wenguanguo or Xanthoceras Sorbifolia.

6. The method of claim 1 , wherein the extract is obtained from the branches of Wenguanguo or Xanthoceras Sorbifolia.

7. The method of claim 1 , wherein the extract is obtained from the stems of Wenguanguo or Xanthoceras Sorbifolia.

8. The method of claim 1 , wherein the extract is obtained by a method comprising the steps of:

(a) extracting Wenguanguo powder with organic solvents or ethanol to obtain an organic extract;

(b) collecting the organic extract;

(c) refluxing the organic extract to obtain a second extract;

(d) removing the organic solvent or ethanol from second aqueous extracts;

(e) drying and sterilizing the second extract to obtain a crude extract powder;

(f) fractionating the crude extract powder into components and saponins using HPLC and FPLC chromatography with silica gel, C18 and other equivalent solid phase materials;

(g) monitoring absorption wavelength at 207 nm or 254 nm;

(h) identifying the saponins of the crude extract powder with MTT cytotoxic assay;

(i) purifying saponins of the crude extract powder with FPLC to obtain one or more fractions of saponins; and

(j) isolating a desired fraction comprising saponin compounds using preparative HPLC.

9. The method of claim 1 , wherein the extract is administered with a pharmaceutically suitable carrier.

10. The method of claim 1 , wherein the cancer is breast cancer.

11. The method of claim 1 , wherein the cancer is leukocyte cancer.

12. The method of claim 1 , wherein the cancer is liver cancer.

13. The method of claim 1 , wherein the cancer is ovary cancer.

14. The method of claim 1 , wherein the cancer is bladder cancer.

15. The method of claim 1 , wherein the cancer is prostate cancer.

16. The method of claim 1 , wherein the cancer is bone cancer.

17. The method of claim 1 , wherein the cancer is brain cancer.

Assignments (4)
CHANGE OF ASSIGNEE ADDRESS Recorded May 9, 2014
From: PACIFIC ARROW LIMITED
To: PACIFIC ARROW LIMITED
Reel/Frame 032859/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2010
From: BAYLOR COLLEGE OF MEDICINE
To: PACIFIC ARROW LIMITED
Reel/Frame 025070/0784 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 13, 2010
From: MAK, MAY SUNG; WANG, YUN
To: PACIFIC ARROW LIMITED
Reel/Frame 024226/0374 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2010
From: CHAN, PUI-KWONG
To: BAYLOR COLLEGE OF MEDICINE
Reel/Frame 024107/0991 →
Continuity (12)
Continuation 11117760 · Apr 27, 2005
Continuation In Part 10906303 · Feb 14, 2005
Continuation In Part PCTUS2004043465 · Dec 23, 2004
Continuation In Part PCTUS2004033359 · Oct 8, 2004
Continuation In Part 10471384
Continuation In Part 09944805 · Aug 31, 2001
Provisional Application 60532101 · Dec 23, 2003
Provisional Application 60509851 · Oct 9, 2003
Provisional Application 60617379 · Oct 8, 2004
Provisional Application 60613811 · Sep 27, 2004
Provisional Application 60607858 · Sep 7, 2004
Related Publication 20100204169A1 · Aug 12, 2010